The proceeds from the financing will allow Shoreline to continue the advancement of its proprietary iPSC platform focused on developing next generation natural killer (NK) cell and macrophage-cell therapies, create potent and persistent NK cell-specific Chimeric Antigen Receptors (CARs) as well as switchable CAR-NK cell engagers and macrophage-specific CARs to treat blood cancers, solid tumors, and other health conditions.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

11408 Sorrento Valley Rd.
San Diego, CA 92121
USA

Phone

Undisclosed

Website

www.shorelinebio.com

Email Address

[email protected]

Overview

To establish safe, effective, and affordable cell-based immunotherapies for the treatment of seriously ill patients. Through innovative thinking and tenacity we strive to discover and develop clinically effective immunotherapies using intelligently engineered iPSC-derived allogeneic cells to save lives.

Profile

Social Media

Shoreline Biosciences Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Kleanthis Xanthopoulos

Co-Founder

Steven Holtzman

Co-Founder

Daniel Kaufman

Co-Founder

William Sandborn

Browse more venture capital transactions:

Prev: 11/3/2021: Archive.ai venture capital transaction
Next: 11/3/2021: Cambridge Epigenetix venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to record every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary